Torys is pleased to announce that we have been awarded Canadian Financial and Corporate Firm of the Year 2020 at the Legal Media Group (LMG) Life Sciences Awards.
Additionally, we have also been awarded Impact Deal of the Year—Canada for advising Fibrocor Therapeutics Inc. in its expanded licensing and collaboration agreement with Galapagos NV. The Torys team included Cheryl Reicin and Jacob Posen (corporate/life sciences), Leah Frank, Michele Cousens and Shane Thomas (securities) and Saira Bhojani (tax).
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. Galapagos discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. In January 2019, Galapagos announced a collaboration with Fibrocor for a small molecule inhibitor program focused on an undisclosed fibrotic target. Under the expanded collaboration announced January 2020, Galapagos receives the exclusive option to inlicense a total of four additional novel target programs. As part of the transaction, Galapagos also takes an equity position in Fibrocor. You can learn more about our work on this transaction by reading the deal description.
The LMG Life Sciences Awards are a celebration of individuals and firms who are responsible for the most innovative and challenging life sciences work from the past year. View the LMG website to find out more.
Join our Life Sciences team in its webinar series as they bring together other practice areas of the firm to discuss the latest legal and regulatory developments at all stages of the sector’s complex life cycle.